Apollo Therapeutics

Apollo Therapeutics is a pioneering biopharmaceutical company dedicated to rapidly advancing a robust pipeline of potentially transformative therapeutic programs. Built upon breakthrough discoveries and strong collaborations with world-leading universities and scientists, Apollo Therapeutics identifies programs with compelling biological hypotheses and the potential to create meaningful new treatment options. The company's innovative portfolio-based model leverages a centralized team of drug development experts who rigorously evaluate therapeutic programs in an objective, data-driven manner, prioritizing critical experiments to de-risk programs early.

Apollo Therapeutics is committed to scaling a robust and potentially transformative pipeline, with a focus on oncology, major inflammatory disorders, and rare diseases. The company's unique approach was established through partnerships with Cambridge, Imperial College London, and University College London, along with AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation.

Apollo Therapeutics is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund and is expanding its operations. Apollo Therapeutics looks forward to build on existing collaborations, foster new relationships, and in-license drug candidates from new partners, further solidifying its position as a leader in biopharmaceutical innovation. We invite the management team at Apollo Therapeutics to create a customized and exclusive company showcase and product listing on our platform.